TAO Synergies (TAOX) Other Non Operating Income (2022 - 2026)
TAO Synergies' (TAOX) quarterly Other Non Operating Income came in at $995000.0 in Q2 2026, up 1066.02% on a YoY basis from $85333.1 in Q2 2025, and up 160.3% quarter-over-quarter from -$1.6 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Other Non Operating Income (2022 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Other Non Operating Income for 5 consecutive years, with $995000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non Operating Income rose 1066.02% year-over-year to $995000.0; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (up 2031.56% YoY), and the FY2025 full-year result was $5.6 million, up 438.08% from the prior year.
- Other Non Operating Income climbed to $995000.0 in Q2 2026 per TAOX's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $5.6 million in Q4 2025 and bottomed at -$2.5 million in Q2 2023.
- Historically, Other Non Operating Income has averaged $467160.0 across 5 years, with a median of $141000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Other Non Operating Income soared 9640.68% in 2025, then slumped 1988.61% in 2026.
- Over 5 years, Other Non Operating Income stood at $1.8 million in 2022, then slumped by 70.02% to $546000.0 in 2023, then tumbled by 110.81% to -$59000.0 in 2024, then jumped by 9640.68% to $5.6 million in 2025, then tumbled by 82.32% to $995000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $995000.0, -$1.6 million, and $5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 995,000.00 |
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | -103,000.00 |
| Mar 31, 2025 | -79,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | -22,000.00 |
| Jun 30, 2024 | 141,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 546,000.00 |
| Sep 30, 2023 | 969,000.00 |
| Jun 30, 2023 | -2.48 Mn |
| Mar 31, 2023 | 225,800.00 |
| Dec 31, 2022 | 1.82 Mn |